Beyond targeted

Tango Therapeutics is a biotechnology company developing novel therapies targeting context-dependent vulnerabilities in cancers. Tango’s robust product engine is designed to support the discovery and development of breakthrough medicines that provide deeper, more sustained benefit than today’s targeted therapies, and that extend the benefits of available immuno-oncology agents. The company’s programs are focused in the area of synthetic lethality, the interaction between two genes that causes cell death when both are inactivated.

Year Invested: 2017
Location: Cambridge, Mass.

Recent News

October 31, 2018
Gilead Sciences And Tango Therapeutics Announce Strategic Collaboration To Develop Next-Generation Targeted Immuno-Oncology Therapies

October 10, 2018
Tango Therapeutics Appoints Malte Peters, MD, to Board of Directors

May 9, 2018
Tango Therapeutics Bolsters Expertise in Oncology Translational Research and Clinical Pharmacology with Leadership Expansion

Read More News

Associated Team Members

Cary Pfeffer, M.D.

Alexis Borisy

Barbara Weber, M.D.
Venture Partner